# Novadip raises €10.4 million to complete pivotal bone-graft trial

_Published Monday, September 21, 2026 at 6:07 AM EDT · Capital, Products · Latest · Tier 2 — Notable_

![Novadip raises €10.4 million to complete pivotal bone-graft trial — Primary](https://www.eu-startups.com/wp-content/uploads/2026/09/Novadip-Biosciences.jpg)

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and European Union for NVD003, a graft made from a patient's own stem cells to treat congenital pseudarthrosis of the tibia, and preparation of a US regulatory submission.

Reaching the financing target also opens access to a tranche of an €18 million European Investment Bank venture-debt agreement. Novadip aims for market authorization in 2028, so the product remains in clinical development and is not approved.

## Sources

- [EU-Startups](https://www.eu-startups.com/2026/09/belgiums-novadip-biosciences-raises-e10-4-million-to-fund-pivotal-clinical-trial-and-unlock-eib-loan-tranche/)

---
Canonical: https://techandbusiness.org/newswire/ENGHqiR_e4-p0k2m-8anPX
Published: 2026-09-21T10:07:00.321Z
Story chronology: 2026-09-21T09:40:43.000Z
Retrieved: 2026-09-21T12:30:18.129Z
Publisher: Tech & Business (techandbusiness.org)